PDF(Pubmed)
Abstract：
UNASSIGNED: According to WHO, hypertensive disease is the leading cause of direct maternal mortality accounting for 10-25% in developing countries (James in Heart, 90(12):1499-504). This study compares the combinations of mean arterial pressure (MAP) and uterine artery doppler (UAD) versus serum-free β HCG, pregnancy-associated plasma protein-A, and placental growth factor (PlGF) versus a combination of all variables at 11 to 13+6 as long-term predictors of pregnancy-induced hypertension (PIH).
UNASSIGNED: A prospective, observational cohort study recruited 97 primigravidae at 11 to 13+6 weeks gestation at GMCH. Follow-up was done at 32-34 weeks and before delivery. Development of PIH, mode of delivery, birthweight, maternal and fetal adverse outcomes were documented, analyzed and compared among three groups. In Group A-biophysical markers, Group B-biochemical markers and in Group C all variables were used.
UNASSIGNED: The mean age, maternal weight, height and BMI of patients developing gestational hypertension were 30 ± 5 years, 64.3 ± 12.5 kg, 155.8 ± 5.5 cm and 26.4 ± 4.1, respectively. Out of the 3, Group C is the best screening test for predicting the overall chance of development of gestational hypertension with a sensitivity of 97.37% and specificity of 38.98% (p < 0.0001). A mild negative correlation is seen between PlGF levels and severity of PIH (p-0.0382).
UNASSIGNED: MAP and UAD can be easily incorporated into the infrastructure of most hospitals. If the biochemical test kits are made available at a low cost through available programs such as JSSK, it can bring down the MMR by preventing gestational hypertension.
UNASSIGNED: A prospective, observational cohort study recruited 97 primigravidae at 11 to 13+6 weeks gestation at GMCH. Follow-up was done at 32-34 weeks and before delivery. Development of PIH, mode of delivery, birthweight, maternal and fetal adverse outcomes were documented, analyzed and compared among three groups. In Group A-biophysical markers, Group B-biochemical markers and in Group C all variables were used.
UNASSIGNED: The mean age, maternal weight, height and BMI of patients developing gestational hypertension were 30 ± 5 years, 64.3 ± 12.5 kg, 155.8 ± 5.5 cm and 26.4 ± 4.1, respectively. Out of the 3, Group C is the best screening test for predicting the overall chance of development of gestational hypertension with a sensitivity of 97.37% and specificity of 38.98% (p < 0.0001). A mild negative correlation is seen between PlGF levels and severity of PIH (p-0.0382).
UNASSIGNED: MAP and UAD can be easily incorporated into the infrastructure of most hospitals. If the biochemical test kits are made available at a low cost through available programs such as JSSK, it can bring down the MMR by preventing gestational hypertension.
摘要：
■根据世界卫生组织，高血压疾病是发展中国家直接孕产妇死亡率的主要原因，占10-25%(JamesinHeart，90（12）：1499-504）。这项研究比较了平均动脉压（MAP）和子宫动脉多普勒（UAD）与无血清βHCG的组合，妊娠相关血浆蛋白A,和胎盘生长因子（PlGF）与11至136个变量的组合作为妊娠高血压（PIH）的长期预测因子。
■预期，观察性队列研究在GMCH妊娠11~13+6周时招募了97只初生科。在分娩前32-34周进行随访。PIH的发展,交货方式,出生体重,母亲和胎儿的不良结局被记录，分析比较三组。在A组生物物理标记中，B组生化标志物和C组使用所有变量。
■平均年龄，产妇体重,妊娠期高血压患者的身高和BMI为30±5岁，64.3±12.5kg,分别为155.8±5.5cm和26.4±4.1cm。在3组中，C组是预测妊娠期高血压疾病发展总体机会的最佳筛查测试，其敏感性为97.37％，特异性为38.98％（p<0.0001）。在PlGF水平和PIH的严重程度之间观察到轻度负相关(p-0.0382)。
■MAP和UAD可以轻松地整合到大多数医院的基础设施中。如果通过JSSK等可用程序以低成本提供生化检测试剂盒，它可以通过预防妊娠期高血压来降低MMR。
■预期，观察性队列研究在GMCH妊娠11~13+6周时招募了97只初生科。在分娩前32-34周进行随访。PIH的发展,交货方式,出生体重,母亲和胎儿的不良结局被记录，分析比较三组。在A组生物物理标记中，B组生化标志物和C组使用所有变量。
■平均年龄，产妇体重,妊娠期高血压患者的身高和BMI为30±5岁，64.3±12.5kg,分别为155.8±5.5cm和26.4±4.1cm。在3组中，C组是预测妊娠期高血压疾病发展总体机会的最佳筛查测试，其敏感性为97.37％，特异性为38.98％（p<0.0001）。在PlGF水平和PIH的严重程度之间观察到轻度负相关(p-0.0382)。
■MAP和UAD可以轻松地整合到大多数医院的基础设施中。如果通过JSSK等可用程序以低成本提供生化检测试剂盒，它可以通过预防妊娠期高血压来降低MMR。
